179 related articles for article (PubMed ID: 35137541)
21. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
22. Immune Regulation of Interleukin-27 in Malignant Pleural Effusion.
Li S; You WJ; Zhang JC; Zhou Q; Shi HZ
Chin Med J (Engl); 2015 Jul; 128(14):1932-41. PubMed ID: 26168835
[TBL] [Abstract][Full Text] [Related]
23. Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade.
Chen SF; Lin YS; Jao SW; Chang YC; Liu CL; Lin YJ; Nieh S
PLoS One; 2013; 8(5):e54659. PubMed ID: 23658677
[TBL] [Abstract][Full Text] [Related]
24. Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.
Xu C; Yu L; Zhan P; Zhang Y
Eur J Med Res; 2014 May; 19(1):23. PubMed ID: 24887477
[TBL] [Abstract][Full Text] [Related]
25. The M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer.
Wu MF; Lin CA; Yuan TH; Yeh HY; Su SF; Guo CL; Chang GC; Li KC; Ho CC; Chen HW
Cancer Immunol Immunother; 2021 May; 70(5):1435-1450. PubMed ID: 33175182
[TBL] [Abstract][Full Text] [Related]
26. IL-26 promotes the pathogenesis of malignant pleural effusion by enhancing CD4
Niu Y; Ye L; Peng W; Wang Z; Wei X; Wang X; Li Y; Zhang S; Xiang X; Zhou Q
J Leukoc Biol; 2021 Jul; 110(1):39-52. PubMed ID: 33847412
[TBL] [Abstract][Full Text] [Related]
27. Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.
Yeh HH; Chang WT; Lu KC; Lai WW; Liu HS; Su WC
PLoS One; 2013; 8(9):e75287. PubMed ID: 24086497
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer.
Hu CY; Zhang YH; Wang T; Chen L; Gong ZH; Wan YS; Li QJ; Li YS; Zhu B
Clin Exp Immunol; 2016 Oct; 186(1):106-14. PubMed ID: 27447482
[TBL] [Abstract][Full Text] [Related]
29. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
[TBL] [Abstract][Full Text] [Related]
30. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion.
Yeh HH; Lai WW; Chen HH; Liu HS; Su WC
Oncogene; 2006 Jul; 25(31):4300-9. PubMed ID: 16518408
[TBL] [Abstract][Full Text] [Related]
31. [Level of soluble programmed death ligand 1 in pleural effusion and peripheral blood of patients with tuberculous pleural effusion and its clinical implications].
Pan X; Xing Y; Shi M; Zhou T; Qian B; Chen Y
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1543-6. PubMed ID: 25146741
[TBL] [Abstract][Full Text] [Related]
32. IL-17A-Producing γδT Cells Inhibit the Formation of Malignant Pleural Effusions.
Wei XS; Pei XB; Liu YL; Wu XZ; Shi HZ; Zhou Q
Am J Respir Cell Mol Biol; 2019 Aug; 61(2):174-184. PubMed ID: 30608868
[TBL] [Abstract][Full Text] [Related]
33. Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
Marazioti A; Kairi CA; Spella M; Giannou AD; Magkouta S; Giopanou I; Papaleonidopoulos V; Kalomenidis I; Snyder LA; Kardamakis D; Stathopoulos GT
PLoS One; 2013; 8(8):e71207. PubMed ID: 23967166
[TBL] [Abstract][Full Text] [Related]
34. Microarray expression profile and analysis of circular RNA regulatory network in malignant pleural effusion.
Wen Y; Wang Y; Xing Z; Liu Z; Hou Z
Cell Cycle; 2018; 17(24):2819-2832. PubMed ID: 30563416
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
36. Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion.
Niu Y; Zhou Q
Cell Mol Life Sci; 2022 Mar; 79(4):194. PubMed ID: 35298721
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of pleural interleukin 17 and carcinoembryonic antigen in lung cancer patients with malignant pleural effusions.
Xu CH; Zhan P; Yu LK; Zhang XW
Tumour Biol; 2014 Feb; 35(2):1599-603. PubMed ID: 24072496
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer.
Wang Y; Chen Z; Chen J; Pan J; Zhang W; Pan Q; Ding H; Lin X; Wen X; Li Y; Meng QH
Clin Chim Acta; 2013 Jun; 421():230-5. PubMed ID: 23523589
[TBL] [Abstract][Full Text] [Related]
39. [Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines TH1/TH2 of lung carcinoma patients with malignant pleural effusion].
Kang MQ; Cao YP; Deng F
Ai Zheng; 2008 Feb; 27(2):210-3. PubMed ID: 18279624
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
Cui R; Takahashi F; Ohashi R; Yoshioka M; Gu T; Tajima K; Unnoura T; Iwakami S; Hirama M; Ishiwata T; Iwase A; Takahashi K
Lung Cancer; 2009 Mar; 63(3):368-74. PubMed ID: 18752867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
